Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Hematology"
DOI: 10.1002/ajh.25016
Abstract: Therapeutic complement inhibition by eculizumab has revolutionized the treatment of paroxysmal nocturnal hemoglobinuria (PNH) with a major impact on its natural history. Nevertheless, emerging unmet clinical needs may benefit from the development of novel complement… read more here.
Keywords: paroxysmal nocturnal; inhibition; nocturnal hemoglobinuria; complement inhibition ... See more keywords
Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria
Sign Up to like & getrecommendations! Published in 2021 at "American Journal of Hematology"
DOI: 10.1002/ajh.26187
Abstract: Paroxysmal nocturnal hemoglobinuria (PNH) is an uncommon bone marrow disorder associated with hemolytic anemia, thrombosis, and cytopenias. Prior to 2007, treatment for PNH was limited and patients with PNH were treated with corticosteroids, anticoagulation for… read more here.
Keywords: treatment; paroxysmal nocturnal; iron overload; nocturnal hemoglobinuria ... See more keywords
Paroxysmal nocturnal hemoglobinuria: Where we stand
Sign Up to like & getrecommendations! Published in 2023 at "American Journal of Hematology"
DOI: 10.1002/ajh.26832
Abstract: For the last 20 years, therapy of paroxysmal nocturnal hemoglobinuria (PNH) relied—up until recently—on antibody based terminal complement inhibitionon. PNH pathophysiology—a mutational defect leading to partial or complete absence of complement‐regulatory proteins on blood cells—leads to… read more here.
Keywords: hemoglobinuria stand; complement; nocturnal hemoglobinuria; paroxysmal nocturnal ... See more keywords
Paroxysmal nocturnal hemoglobinuria: Where are we going
Sign Up to like & getrecommendations! Published in 2023 at "American Journal of Hematology"
DOI: 10.1002/ajh.26882
Abstract: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare nonmalignant clonal hematological disorder that is characterized by a deficiency of the GPI‐linked complement regulators on the membrane of hematopoietic cells, which renders them susceptible to complement‐mediated damage.… read more here.
Keywords: hemoglobinuria going; complement; nocturnal hemoglobinuria; paroxysmal nocturnal ... See more keywords
Nationwide study of paroxysmal nocturnal hemoglobinuria in South Korea: paradox of eculizumab
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-04133-z
Abstract: Eculizumab is effective in managing patients with paroxysmal nocturnal hemoglobinuria (PNH). In South Korea, the financial support for eculizumab therapy is extended by the National Health Insurance Services (NHIS) only to patients with high-risk PNH… read more here.
Keywords: group; paroxysmal nocturnal; eculizumab; nocturnal hemoglobinuria ... See more keywords
Battle of the clones: paroxysmal nocturnal hemoglobinuria vs myelodysplastic syndrome
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-04134-y
Abstract: Dear Editor, Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disorder of hematopoietic stem cell characterized by mutations in the PIGA gene leading to complementmediated lysis [1]. Approved in 2009, eculizumab is the first specific… read more here.
Keywords: analysis; paroxysmal nocturnal; myelodysplastic syndrome; nocturnal hemoglobinuria ... See more keywords
Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Experimental Medicine"
DOI: 10.1007/s10238-022-00830-3
Abstract: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening acquired blood disease characterized by chronic complement-mediated hemolysis and thrombosis. On May 14, 2021, the US FDA approved a new targeted C3 therapy Empaveli (pegcetacoplan), once called… read more here.
Keywords: paroxysmal nocturnal; nocturnal hemoglobinuria; novel targeted; pegcetacoplan ... See more keywords
Screening for paroxysmal nocturnal hemoglobinuria (PNH) in patients presenting with cerebral sinovenous thrombosis (CSVT): Results of a FLAER based flowcytometry study in Indian patients
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Thrombosis and Thrombolysis"
DOI: 10.1007/s11239-019-01982-y
Abstract: Patients with paroxysmal nocturnal hemoglobinuria (PNH) may present with thrombosis at unusual sites, of which cerebral sinovenous thrombosis (CSVT) is one and screening for PNH is recommended in this condition. Though many patients diagnosed with… read more here.
Keywords: flowcytometry; pnh; paroxysmal nocturnal; nocturnal hemoglobinuria ... See more keywords
Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Hematology"
DOI: 10.1007/s12185-018-2409-3
Abstract: In paroxysmal nocturnal hemoglobinuria (PNH), various symptoms due to intravascular hemolysis exert a negative impact on patients’ quality of life (QOL). To determine clinical factors related with improvements in QOL in PNH patients treated, we… read more here.
Keywords: eculizumab treatment; treatment; paroxysmal nocturnal; nocturnal hemoglobinuria ... See more keywords
Treatment of paroxysmal nocturnal hemoglobinuria in pregnancy with eculizumab: A case report
Sign Up to like & getrecommendations! Published in 2021 at "Case Reports in Women's Health"
DOI: 10.1016/j.crwh.2021.e00294
Abstract: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease caused by mutations in hematopoietic stem cells leading to pancytopenia and a predisposition for thromboembolic events. In pregnancy, these manifestations can be amplified, leading to increased neonatal… read more here.
Keywords: pregnancy; treatment; case; paroxysmal nocturnal ... See more keywords
Even mild hemolysis in paroxysmal nocturnal hemoglobinuria could severely compromise the quality of life due to long-term sustained intolerant fatigue
Sign Up to like & getrecommendations! Published in 2020 at "Leukemia Research Reports"
DOI: 10.1016/j.lrr.2020.100224
Abstract: Fatigue is one of the most common symptoms associated with paroxysmal nocturnal hemoglobinuria (PNH), a rare acquired disorder of hematopoietic stem cells. While it directly impairs lifestyle leading to poor quality of life (QOL), it… read more here.
Keywords: fatigue; mild hemolysis; paroxysmal nocturnal; nocturnal hemoglobinuria ... See more keywords